Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 7/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.56 |
| ▸ | BCR | P11274 | 4/20 | 0.56 |
| ▸ | BRAF | P15056 | 8/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24007134 | 0.89 | ABL1 (0.60) | ABL1MKNK2MKNK1BCRBRAF | |
| SCHEMBL24374421 | 0.84 | BRAF (0.68) | ABL1MKNK2MKNK1BCRBRAF | |
| SCHEMBL24007593 | 0.82 | ABL1 (0.58) | ABL1MKNK2MKNK1BCRBRAF | |
| SCHEMBL24007716 | 0.81 | ABL1 (0.57) | ABL1MKNK2MKNK1BCRBRAF | |
| SCHEMBL23795596 | 0.81 | ABL1 (0.57) | ABL1MKNK2MKNK1BCRBRAF | |
| SCHEMBL24007717 | 0.81 | ABL1 (0.57) | ABL1MKNK2MKNK1BCRBRAF | |
| SCHEMBL26007840 | 0.80 | BRAF (0.59) | ABL1MKNK2MKNK1BCRBRAF | |
| SCHEMBL24007130 | 0.80 | BRAF (0.61) | ABL1MKNK2MKNK1BCRBRAF | |
| SCHEMBL23795601 | 0.80 | BRAF (0.56) | ABL1MKNK2MKNK1BCRBRAF | |
| SCHEMBL24007133 | 0.79 | ABL1 (0.55) | ABL1MKNK2MKNK1BCRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183204-A9 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183204-A9 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220127246-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127246-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ABL1 18/4885MKNK2 585/4885MKNK1 672/4885 |
| US-20230183204-A9 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ABL1 18/4885MKNK2 585/4885MKNK1 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.